KR20230107291A - PPARγ 조절제 및 사용 방법 - Google Patents
PPARγ 조절제 및 사용 방법 Download PDFInfo
- Publication number
- KR20230107291A KR20230107291A KR1020237019226A KR20237019226A KR20230107291A KR 20230107291 A KR20230107291 A KR 20230107291A KR 1020237019226 A KR1020237019226 A KR 1020237019226A KR 20237019226 A KR20237019226 A KR 20237019226A KR 20230107291 A KR20230107291 A KR 20230107291A
- Authority
- KR
- South Korea
- Prior art keywords
- carbonyl
- carboxamide
- pyrazole
- methoxypyridin
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063111354P | 2020-11-09 | 2020-11-09 | |
| US63/111,354 | 2020-11-09 | ||
| PCT/US2021/058473 WO2022099144A1 (en) | 2020-11-09 | 2021-11-08 | ΡΡΑRγ MODULATORS AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230107291A true KR20230107291A (ko) | 2023-07-14 |
Family
ID=78820026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237019226A Pending KR20230107291A (ko) | 2020-11-09 | 2021-11-08 | PPARγ 조절제 및 사용 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606541B2 (https=) |
| EP (1) | EP4240736A1 (https=) |
| JP (1) | JP2023549123A (https=) |
| KR (1) | KR20230107291A (https=) |
| CN (1) | CN116635380A (https=) |
| AR (1) | AR124034A1 (https=) |
| AU (1) | AU2021376300A1 (https=) |
| CA (1) | CA3200524A1 (https=) |
| IL (1) | IL302543A (https=) |
| MX (1) | MX2023005371A (https=) |
| TW (1) | TW202233598A (https=) |
| WO (1) | WO2022099144A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202345821A (zh) * | 2022-05-09 | 2023-12-01 | 日商衛材R&D企管股份有限公司 | PPAR-γ調節劑的固體晶型及其使用方法 |
| CN117800895A (zh) * | 2022-09-30 | 2024-04-02 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
| CN116621792B (zh) * | 2023-05-16 | 2025-02-25 | 常州大学 | 一种制备n-正丁基-1,2-苯并异噻唑啉-3-酮-1-氧化物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0717106A2 (pt) | 2006-09-21 | 2013-10-08 | Piramal Life Sciences Ltd | Compostos para o tratamento de distúrbios metabólicos |
| CA2754446A1 (en) | 2009-03-05 | 2010-09-10 | Daiichi Sankyo Company, Limited | Pyridine derivative |
| US9562031B1 (en) | 2015-09-12 | 2017-02-07 | Sequoia Sciences, Inc. | Phenethyldihydrobenzodioxolones and methods of use |
| CA2998753A1 (en) * | 2015-09-18 | 2017-03-23 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
| EP3498694A1 (en) | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
-
2021
- 2021-11-08 AU AU2021376300A patent/AU2021376300A1/en active Pending
- 2021-11-08 JP JP2023527349A patent/JP2023549123A/ja active Pending
- 2021-11-08 MX MX2023005371A patent/MX2023005371A/es unknown
- 2021-11-08 US US17/521,666 patent/US12606541B2/en active Active
- 2021-11-08 CN CN202180089308.6A patent/CN116635380A/zh active Pending
- 2021-11-08 EP EP21816611.4A patent/EP4240736A1/en active Pending
- 2021-11-08 CA CA3200524A patent/CA3200524A1/en active Pending
- 2021-11-08 KR KR1020237019226A patent/KR20230107291A/ko active Pending
- 2021-11-08 WO PCT/US2021/058473 patent/WO2022099144A1/en not_active Ceased
- 2021-11-08 IL IL302543A patent/IL302543A/en unknown
- 2021-11-09 AR ARP210103111A patent/AR124034A1/es unknown
- 2021-11-09 TW TW110141725A patent/TW202233598A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR124034A1 (es) | 2023-02-08 |
| CA3200524A1 (en) | 2022-05-12 |
| US20230062861A1 (en) | 2023-03-02 |
| CN116635380A (zh) | 2023-08-22 |
| EP4240736A1 (en) | 2023-09-13 |
| MX2023005371A (es) | 2023-05-22 |
| JP2023549123A (ja) | 2023-11-22 |
| US12606541B2 (en) | 2026-04-21 |
| AU2021376300A1 (en) | 2023-06-22 |
| AU2021376300A9 (en) | 2024-10-10 |
| IL302543A (en) | 2023-07-01 |
| WO2022099144A1 (en) | 2022-05-12 |
| TW202233598A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019240299B2 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| KR101787680B1 (ko) | 키나아제 억제제 및 이의 용도 | |
| KR101659193B1 (ko) | Btk 활성의 억제제로서의 헤테로아릴 피리돈 및 아자-피리돈 화합물 | |
| KR101862327B1 (ko) | 피리돈 및 아자-피리돈 화합물 및 사용 방법 | |
| WO2020005882A1 (en) | Heteroaryl compounds for treating huntington's disease | |
| WO2025049746A1 (en) | Compositions comprising werner syndrome helicase inhibitors and methods of using the same | |
| KR20230107291A (ko) | PPARγ 조절제 및 사용 방법 | |
| US20240025906A1 (en) | Kinase modulators and methods of use thereof | |
| JP2023534837A (ja) | アンドロゲン受容体モジュレーターとしてのインドール化合物 | |
| KR20240031944A (ko) | 암 등의 치료를 위한 shp2 억제제로서의 (s)-1-(5-((피리딘-3-일)티오)피라진-2-일)-4'h,6'h-스피로[피페리딘-4,5'-피롤로[1,2-b]피라졸]-4'-아민 유도체 및 유사 화합물 | |
| TW202327586A (zh) | 葡糖腦苷脂酶活性的小分子調節劑及其用途 | |
| CN118488947A (zh) | 稠环取代的六元杂环化合物及其制法和用途 | |
| RU2846525C2 (ru) | Ингибиторы shp2 фосфатазы и способы их применения | |
| TW202610638A (zh) | 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法 | |
| US20260055095A1 (en) | Novel compounds and uses thereof | |
| HK1223089B (en) | Kinase inhibitor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |